AU2019220935B2 - Method for generating cells of the T cell lineage - Google Patents

Method for generating cells of the T cell lineage Download PDF

Info

Publication number
AU2019220935B2
AU2019220935B2 AU2019220935A AU2019220935A AU2019220935B2 AU 2019220935 B2 AU2019220935 B2 AU 2019220935B2 AU 2019220935 A AU2019220935 A AU 2019220935A AU 2019220935 A AU2019220935 A AU 2019220935A AU 2019220935 B2 AU2019220935 B2 AU 2019220935B2
Authority
AU
Australia
Prior art keywords
cells
cell
beads
progenitor
kda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019220935A
Other languages
English (en)
Other versions
AU2019220935A1 (en
Inventor
Mahmood MOHTASHAMI
Ashton TROTMAN-GRANT
Juan Carlos Zuniga-Pflucker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunnybrook Research Institute
Original Assignee
Sunnybrook Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunnybrook Research Institute filed Critical Sunnybrook Research Institute
Publication of AU2019220935A1 publication Critical patent/AU2019220935A1/en
Application granted granted Critical
Publication of AU2019220935B2 publication Critical patent/AU2019220935B2/en
Priority to AU2025204516A priority Critical patent/AU2025204516A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068—General culture methods using substrates
    • C12N5/0075—General culture methods using substrates using microcarriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
AU2019220935A 2018-02-14 2019-02-14 Method for generating cells of the T cell lineage Active AU2019220935B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025204516A AU2025204516A1 (en) 2018-02-14 2025-06-17 Method for generating cells of the T cell lineage

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862630497P 2018-02-14 2018-02-14
US62/630,497 2018-02-14
PCT/CA2019/050181 WO2019157597A1 (en) 2018-02-14 2019-02-14 Method for generating cells of the t cell lineage

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025204516A Division AU2025204516A1 (en) 2018-02-14 2025-06-17 Method for generating cells of the T cell lineage

Publications (2)

Publication Number Publication Date
AU2019220935A1 AU2019220935A1 (en) 2020-10-01
AU2019220935B2 true AU2019220935B2 (en) 2025-03-20

Family

ID=67619677

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019220935A Active AU2019220935B2 (en) 2018-02-14 2019-02-14 Method for generating cells of the T cell lineage
AU2025204516A Pending AU2025204516A1 (en) 2018-02-14 2025-06-17 Method for generating cells of the T cell lineage

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025204516A Pending AU2025204516A1 (en) 2018-02-14 2025-06-17 Method for generating cells of the T cell lineage

Country Status (8)

Country Link
US (2) US12467034B2 (cg-RX-API-DMAC7.html)
EP (1) EP3752602A4 (cg-RX-API-DMAC7.html)
JP (3) JP2021514185A (cg-RX-API-DMAC7.html)
KR (1) KR20200121817A (cg-RX-API-DMAC7.html)
CN (1) CN112041431A (cg-RX-API-DMAC7.html)
AU (2) AU2019220935B2 (cg-RX-API-DMAC7.html)
CA (1) CA3091158A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019157597A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3091158A1 (en) 2018-02-14 2019-08-22 Sunnybrook Research Institute Method for generating cells of the t cell lineage
EP4237542A1 (en) * 2020-10-28 2023-09-06 Sangamo Therapeutics, Inc. Generation of cd4+ effector and regulatory t cells from human pluripotent stem cells
AU2021386370A1 (en) 2020-11-24 2023-06-22 Lyell Immunopharma, Inc. Methods for making, compositions comprising, and methods of using rejuvenated t cells
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
EP4289940A4 (en) * 2021-02-05 2025-02-26 National University Corporation Kobe University ?? T-CELLS FROM INDUCED PLURIPOTENT STEM CELLS AND PRODUCTION PROCESSES THEREFOR
AU2022253223A1 (en) 2021-04-07 2023-09-28 Century Therapeutics, Inc. Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
CA3210702A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Gene transfer vectors and methods of engineering cells
WO2022241558A1 (en) * 2021-05-18 2022-11-24 The University Of British Columbia A method for producing blood progenitor and progenitor t cells, resulting cells and methods and uses thereof
WO2023129937A1 (en) 2021-12-29 2023-07-06 Century Therapeutics, Inc. Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
IL314801A (en) 2022-02-22 2024-10-01 Juno Therapeutics Inc Proteinase 3 (PR3) Chimeric Autoantigen Receptor T Cells and Related Methods and Uses
JP2025515095A (ja) 2022-05-04 2025-05-13 センチュリー セラピューティクス，インコーポレイテッド Ｈｌａ－ｅおよびｈｌａ－ｇ導入遺伝子を用いて操作された細胞
US20250090582A1 (en) 2022-06-08 2025-03-20 Century Therapeutics, Inc. Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
EP4536814A1 (en) 2022-06-08 2025-04-16 Century Therapeutics, Inc. Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereof
CN119630695A (zh) 2022-06-08 2025-03-14 世纪治疗股份有限公司 表达cd16变体和nkg2d的遗传工程化细胞及其用途
WO2024102838A1 (en) 2022-11-09 2024-05-16 Century Therapeutics, Inc. Engineered interleukin-7 receptors and uses thereof
CN120435498A (zh) 2022-11-10 2025-08-05 世纪治疗股份有限公司 具有抗-nectin4嵌合抗原受体的基因工程化细胞及其用途
KR20250150555A (ko) * 2023-01-27 2025-10-20 노치 테라퓨틱스 (캐나다) 인크. 줄기세포/전구세포로부터 t 세포 계통 모집단을 생성하는 방법
WO2025101938A2 (en) 2023-11-10 2025-05-15 Century Therapeutics, Inc. Genetically engineered cells having multi-transmembrane domain chimeric antigen receptors utilizing g protein-coupled receptor scaffolds, and uses thereof
WO2025106626A1 (en) 2023-11-15 2025-05-22 Century Therapeutics, Inc. Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof
WO2025207795A1 (en) 2024-03-26 2025-10-02 Juno Therapeutics, Inc. Genetically engineered cells having anti-cd33 / anti-cd123 chimeric antigen receptors, and uses thereof
WO2025207798A1 (en) 2024-03-26 2025-10-02 Century Therapeutics, Inc. Genetically engineered cells having anti-cd123 chimeric antigen receptors, and uses thereof
US20250332260A1 (en) 2024-04-10 2025-10-30 Garuda Therapeutics, Inc. Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations
US20260083778A1 (en) * 2024-09-20 2026-03-26 Boston Medical Center Corporation Generation of cd4 t cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007027226A2 (en) * 2005-04-28 2007-03-08 Board Of Regents, The University Of Texas System Systems and methods for the production of differentiated cells

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201043699A (en) 2002-03-25 2010-12-16 Takara Bio Inc Process for producing cytotoxic lymphocyte
EP1492816A2 (en) * 2002-04-05 2005-01-05 Lorantis Limited Modulators of the notch signalling pathway and uses thereof in medical treatment
US7575925B2 (en) * 2002-12-10 2009-08-18 Sunnybrook Health Sciences Centre Cell preparations comprising cells of the T cell lineage and methods of making and using them
WO2004064863A1 (en) 2003-01-23 2004-08-05 Lorantis Limited Treatment of autoimmune diseases using an activator for the notch signaling pathway
EP2321407A4 (en) 2008-09-11 2012-07-18 Univ Florida SYSTEM AND METHOD FOR THE PRODUCTION OF T-CELLS
US8772028B2 (en) * 2008-11-07 2014-07-08 Sunnybrook Health Sciences Centre CD34+CD7+CD5+CD1a-human progenitor T-cells produced in vitro and methods of using
US8871510B2 (en) 2009-12-03 2014-10-28 University Of Utah Research Foundation Methods for generating T lymphocytes from hematopoietic stem cells
PL2539441T3 (pl) 2010-02-22 2017-06-30 Université Pierre Et Marie Curie (Paris 6) Podłoże do hodowli komórkowej do wzrostu i różnicowania komórek linii hematopoetycznych
US9834754B2 (en) 2011-11-21 2017-12-05 University Health Network Populations of hematopoietic progenitors and methods of enriching stem cells therefor
JP6449995B2 (ja) * 2014-09-16 2019-01-09 ヒタチ ゾウセン イノバ アクチェンゲゼルシャフト 廃棄物焼却プラントの燃焼チャンバー内で発生するスラグを処理するための方法及び装置
FR3026744B1 (fr) 2014-10-06 2024-04-19 Hopitaux Paris Assist Publique Methode de generation de progeniteurs de cellules t
US10626372B1 (en) * 2015-01-26 2020-04-21 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
WO2016187459A1 (en) 2015-05-20 2016-11-24 The Regents Of The University Of California Method for generating human dendritic cells for immunotherapy
US12076342B2 (en) 2016-04-08 2024-09-03 The Governing Council Of The University Of Toronto Method for generating progenitor t cells from stem and/or progenitor cells and use of same
US20190134169A1 (en) 2016-04-26 2019-05-09 Temple University-Of The Commonwealth System Of Higher Education DLL4-expressing cells and vaccine using the same
ES2931530T3 (es) 2017-02-13 2022-12-30 Hopitaux Paris Assist Publique Método para generar progenitores de células T
CA3091158A1 (en) 2018-02-14 2019-08-22 Sunnybrook Research Institute Method for generating cells of the t cell lineage
EP4326856A4 (en) 2021-04-23 2025-10-08 Sunnybrook Res Inst STEM CELLS COMPRISING AN UNREARRANGED T CELL RECEPTOR (TCR) GENE LOCUS AND METHODS OF USE THEREOF
WO2022241558A1 (en) 2021-05-18 2022-11-24 The University Of British Columbia A method for producing blood progenitor and progenitor t cells, resulting cells and methods and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007027226A2 (en) * 2005-04-28 2007-03-08 Board Of Regents, The University Of Texas System Systems and methods for the production of differentiated cells

Also Published As

Publication number Publication date
EP3752602A1 (en) 2020-12-23
CN112041431A (zh) 2020-12-04
JP2021514185A (ja) 2021-06-10
JP2024016217A (ja) 2024-02-06
US20200399599A1 (en) 2020-12-24
AU2025204516A1 (en) 2025-07-03
JP2026031647A (ja) 2026-02-24
WO2019157597A1 (en) 2019-08-22
US20260043003A1 (en) 2026-02-12
US12467034B2 (en) 2025-11-11
EP3752602A4 (en) 2021-11-24
CA3091158A1 (en) 2019-08-22
KR20200121817A (ko) 2020-10-26
JP7866537B2 (ja) 2026-05-27
AU2019220935A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
US20260043003A1 (en) Method for generating cells of the t cell lineage
Williams et al. Generation of lytic natural killer 1.1+, Ly-49− cells from multipotential murine bone marrow progenitors in a stroma-free culture: definition of cytokine requirements and developmental intermediates
KR102510368B1 (ko) 혈관 콜로니 형성 세포
CA2390281C (en) Hematopoietic differentiation of human embryonic stem cells
US9255249B2 (en) Isolation and purification of hematopoietic stem cells from post-liposuction lipoaspirates
US20080206208A1 (en) Extramedullary adipose tissue cells and use thereof for regenerating hematopoietic and muscular tissues
MXPA06006706A (es) Celulas madre.
US20030124091A1 (en) Endothelial cell derived hematopoietic growth factor
US20210002612A1 (en) Novel method for obtaining t cells from pluripotent stem cells, and uses thereof
EP1458852B1 (en) Compositions for the in vitro derivation and culture of embryonic stem (es) cell lines with germline transmission capability and for the culture of adult stem cells
US20120177618A1 (en) Hematopoietic stromal progenitor cells and uses thereof
WO2005054459A1 (ja) 造血幹細胞あるいは血管内皮前駆細胞の製造方法
US20250090578A1 (en) Method of producing a population of immune cells from pluripotent stem cells
JP3962459B2 (ja) 造血幹細胞の分化・増殖調節方法
WO1999003980A1 (en) Agm-derived stroma cells
WO2008056734A1 (en) Method for producing dendritic cells from human embryonic stem cells
AU2024380899A1 (en) Method of producing an immune cell devoid of endogenous effector functions from pluripotent stem cells
RU2797260C2 (ru) Способ получения предшественников т-клеток
WO2025086007A1 (en) Soluble notch ligands and methods for generating cells of the t cell lineage therewith
Class et al. Patent application title: HEMATOPOIETIC STROMAL PROGENITOR CELLS AND USES THEREOF Inventors: Biju Parekkadan (Cambridge, MA, US) John Miles Milwid (Cambridge, MA, US) Martin Leon Yarmush (Newton, MA, US) Assignees: Massachusetts Institute of Technology THE GENERAL HOSPITAL CORPORATION d/b/a MASSACHUSETTS GENERAL HOSPITAL
Ball et al. MSCs in Pediatric Hematopoietic Stem Cell Transplantation
Crawford Human peripheral blood dendritic cells: phenotype, morphology, and function

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)